Cidara Therapeutics, Inc. financial data

Symbol
CDTX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
6310 Nancy Ridge Drive, Suite 101, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
K2 THERAPEUTICS, INC. (to 2/4/2015)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 200 % +49.3%
Quick Ratio 8.19 %
Debt-to-equity 106 %
Return On Equity -219 % -105%
Return On Assets -106 % -108%
Operating Margin -434 % -903%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.05M shares -92.2%
Common Stock, Shares, Outstanding 7.05M shares -92.2%
Entity Public Float 100M USD +202%
Common Stock, Value, Issued 1K USD -88.9%
Weighted Average Number of Shares Outstanding, Basic 6.53M shares +44.7%
Weighted Average Number of Shares Outstanding, Diluted 6.53M shares +44.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 32.3M USD -36.3%
Revenue from Contract with Customer, Excluding Assessed Tax 2.83M USD
Research and Development Expense 61.3M USD +5.65%
General and Administrative Expense 14.6M USD -27.2%
Operating Income (Loss) -140M USD -539%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.5M USD -303%
Income Tax Expense (Benefit) 435K USD
Net Income (Loss) Attributable to Parent -121M USD -262%
Earnings Per Share, Basic -20.5 USD/shares -348%
Earnings Per Share, Diluted -20.5 USD/shares -348%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 127M USD +162%
Accounts Receivable, after Allowance for Credit Loss, Current 1.7M USD -46.5%
Inventory, Net 7.27M USD
Assets, Current 157M USD +168%
Property, Plant and Equipment, Net 561K USD -3.28%
Operating Lease, Right-of-Use Asset 3.04M USD -25.1%
Other Assets, Noncurrent 1.24M USD +17.9%
Assets 162M USD +153%
Accounts Payable, Current 2.97M USD -19%
Employee-related Liabilities, Current 4.93M USD +10.7%
Accrued Liabilities, Current 8.57M USD -27.2%
Liabilities, Current 44.3M USD -11.7%
Operating Lease, Liability, Noncurrent 1.98M USD -40%
Liabilities 46.7M USD -33.3%
Retained Earnings (Accumulated Deficit) -559M USD -27.6%
Stockholders' Equity Attributable to Parent 116M USD
Liabilities and Equity 162M USD +153%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.64M USD +39%
Net Cash Provided by (Used in) Financing Activities -93K USD -100%
Net Cash Provided by (Used in) Investing Activities -23K USD +75.5%
Common Stock, Shares Authorized 50M shares -75%
Common Stock, Shares, Issued 7.05M shares -92.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.76M USD -144%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 127M USD +162%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 83.1M USD +8.31%
Deferred Tax Assets, Gross 84.6M USD +9.64%
Operating Lease, Liability 3.31M USD -24.1%
Payments to Acquire Property, Plant, and Equipment 23K USD -75.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -121M USD -262%
Lessee, Operating Lease, Liability, to be Paid 3.8M USD -28.6%
Property, Plant and Equipment, Gross 3.75M USD +10.9%
Operating Lease, Liability, Current 1.32M USD +36.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.73M USD +3.96%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.66M USD +4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 489K USD -49.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.73M USD
Deferred Tax Assets, Operating Loss Carryforwards 35.5M USD -15.5%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 11.5M USD +4.59%
Operating Lease, Payments 400K USD +33.3%
Deferred Tax Assets, Net of Valuation Allowance 1.5M USD +242%
Share-based Payment Arrangement, Expense 3.08M USD +6.03%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%